SciClone Pharmaceuticals Story Overview

SCLN -- USA Stock  

USD 11.15  0.00  0.00%

Macroaxis does not monitor all media channels or aggregates social signals for SciClone Pharmaceuticals. But even though we do not provide professional-grade financial sentiment analysis on SciClone Pharmaceuticals, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for SciClone Pharmaceuticals. Also please take a look at SciClone Pharmaceuticals Hype Analysis, SciClone Pharmaceuticals Correlation and SciClone Pharmaceuticals Performance.
Sale by Hong Zhao of 12500 shares of SciClone Pharmaceuticals
Filed transaction by Sciclone Pharmaceuticals officer. General open market or private sale of non-derivative or derivative security

SciClone Pharmaceuticals Inc insider trading alert for sale of common stock by Hong Zhao, CEO China Operations, on January 3, 2018. This event was filed by Sciclone Pharmaceuticals with SEC on 2017-06-14. Statement of changes in beneficial ownership - SEC Form 4

Story Momentum

This story impact on price volatility cannot be determined at this time. Please check this story after some time to allow current data to be analyzed.

Similar stores for SciClone Pharmaceuticals

few days ago at www.macroaxis.com 
Exercise of in-the-money or at-the-money derivative position by Cavazza Paolo of 35100 shares of SciClone Phar...
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals executive. Derivative codes exercise of in-the-money or at-the-money derivative security
over a week ago at www.macroaxis.com 
Purchase by Cavazza Paolo of tradable shares of SciClone Pharmaceuticals
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals executive. General open market or private purchase of non-derivative or derivative security
over three weeks ago at http://www.streetinsider.com 
Form S-1A SOLIGENIX, INC.
Street Insider News
StreetInsider.comFull coverage
over a month ago at www.macroaxis.com 
Exercise of in-the-money or at-the-money derivative position by Cavazza Paolo of tradable shares of SciClone P...
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals executive. Derivative codes exercise of in-the-money or at-the-money derivative security
over a month ago at http://bangaloreweekly.com 
Shinko Asset Management Co. Ltd. Reduced shares of SciClone Pharmaceuticals Inc.
news
BangaloreWeeklyFull coverage
over two months ago at www.macroaxis.com 
Purchase by Cavazza Paolo of tradable shares of SciClone Pharmaceuticals
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals executive. General open market or private purchase of non-derivative or derivative security
over two months ago at http://stocknewstimes.com 
Schwartz Investment Counsel Inc. Acquires New Position in Discovery Communications Inc.
news
StockNewsTimesFull coverage
over two months ago at http://bangaloreweekly.com 
HFF Lowered by Zacks Investment Research to Strong Sell
news
BangaloreWeeklyFull coverage
over two months ago at www.macroaxis.com 
Sale by Cavazza Paolo of 500 shares of SciClone Pharmaceuticals
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals executive. General open market or private sale of non-derivative or derivative security
over three months ago at http://bangaloreweekly.com 
Oxford Asset Management Has 693000 Holding in SciClone Pharmaceuticals, Inc.
news
BangaloreWeeklyFull coverage
over three months ago at http://bangaloreweekly.com 
SciClone Pharmaceuticals Inc. Received Purchase Rating at Maxim Group
news
BangaloreWeeklyFull coverage
over three months ago at http://www.whatsonthorold.com 
As Becton Dickinson Shares Rose, St Germain DJ Co Has Decreased Stake Qs Investors Has Increased Its ...
news
Thorold NewsBecton, Dickinson And Company - BDX - Stock Price Today - Zacks ZacksFull coverage
over six months ago at http://www.truebluetribune.com 
GSA Capital Partners LLP Trims Stake in SciClone Pharmaceuticals, Inc. NASDAQ ...
news
GSA Capital Partners LLP lowered its position in shares of SciClone Pharmaceuticals, Inc. by 33.9 percent in the third quarter, according to its most recent disclosure with the SEC.

Number of Employees

Number of Employees Comparative Analysis
  Number of Employees 
      SciClone Pharmaceuticals Comparables 
SciClone Pharmaceuticals is currently under evaluation in number of employees category among related companies. Number of Employees shows total number of permanent full time and part time employees working for a given company and processed through its payroll.

Peers

SciClone Pharmaceuticals Related Equities
GILD  0.09 %   
6.0%
BIIB  0.11 %   
7.0%
CELG  0.51 %   
34.0%
AMGN  0.54 %   
36.0%
BMY  0.6 %   
39.0%
LLY  0.67 %   
44.0%
MRK  0.68 %   
45.0%
PFE  0.8 %   
53.0%
AGN  1.4 %   
93.0%
ABT  1.5 %   
100.0%
Also please take a look at SciClone Pharmaceuticals Hype Analysis, SciClone Pharmaceuticals Correlation and SciClone Pharmaceuticals Performance. Please also try Coins and Tokens Correlation module to utilize digital token correlation table to build portfolio of cryptocurrencies across multiple exchanges.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">